Lipoplus (Omega-3-Acid Triglycerides, Soya-Bean Oil Refined, Triglycerides, Medium Chain)

The omega‑3‑acid triglycerides in Lipoplus are hydrolysed by lipoprotein lipase into free fatty acids after infusion. These fatty acids are incorporated into cell membranes, serve as an energy source, and modulate inflammatory pathways, thereby supplying essential fatty acids and caloric support during parenteral nutrition.

The dose of Lipoplus is individualized by the prescribing clinician based on the patient’s caloric requirements, lipid tolerance, and clinical condition. Dosing calculations consider factors such as body weight, total parenteral nutrition goals, and serum triglyceride levels.

The safety of Lipoplus in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Lipoplus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lipoplus contains a blend of omega‑3‑acid triglycerides, refined soybean oil, and medium‑chain triglycerides, offering a balanced fatty‑acid profile that may reduce inflammation compared with traditional soybean‑only emulsions. Its composition can provide comparable caloric density while potentially improving lipid tolerance in certain patients.

Lipoplus must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the container for any signs of leakage or discoloration and allow the solution to reach room temperature if required by the administration protocol.

Lipoplus is administered intravenously, typically as part of a total parenteral nutrition regimen. It is infused through a sterile infusion set using aseptic technique, and the infusion rate is adjusted according to the prescribed lipid dose and the patient’s tolerance.

Serious risks include severe allergic reactions (anaphylaxis), fat overload syndrome, acute pancreatitis, significant hepatic dysfunction, and pulmonary complications such as fat embolism. Monitoring of triglyceride levels, liver function, and clinical signs of intolerance is essential during therapy.

Lipoplus is contraindicated in patients with known hypersensitivity to any component (including soy or fish oil), those with severe hyperlipidaemia, or individuals with disorders that predispose to fat overload syndrome. Clinicians should evaluate each patient’s medical history before initiating therapy.